Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021
November 05 2021 - 5:02PM
Trading in Novo Nordisk shares by board members, executives and
associated persons on 5 November 2021
Bagsværd,
Denmark, 5 November
2021 — This document discloses
the data of the transaction(s) made in Novo Nordisk shares by the
company’s board members, executives and their associated persons in
accordance with Article 19 of Regulation No. 596/2014 on market
abuse.
The company’s board members, executives and their associated
persons have given Novo Nordisk power of attorney on their behalf
to publish trading in Novo Nordisk shares by the company’s board
members, executives and their associated persons.
Please find in the attached document a statement of such
trading in shares issued by Novo Nordisk.
PublicationDefinitions and background
information:
Publication shall take place no later than three working days
after the trading by board members, executives or their associated
persons. Publication is only required when the total amount of
transactions of a specific board member/executive or his/her
associated persons in any one calendar year has reached EUR 20,000
(calculated individually).
Who are board members, executives and associated
persons?Board members and executives are members of the
Board of Directors and Executive Management, respectively, of Novo
Nordisk A/S. Associated persons are defined as the following
persons associated to a board member/executive: 1) spouse or
cohabitant, 2) children under the age of 18 years, 3) Other
relatives defined as brothers, sisters, parents, grandparents,
children, grandchildren, cousins etc. who have shared the same
household with a board member or executive for a period of at least
one year on the date of the given transaction and 4) any legal
persons, trust, or partnership, the managerial responsibilities of
which are discharged by a board member/executive or by a person
referred to in items 1)-3) above, or which is directly or
indirectly controlled by such a person, or which is set up for the
benefit of such a person, or the economic interests of which are
substantially equivalent to those of such a person.
What is trading/transaction?Trading is any kind
of transaction, including shares and share related securities
purchased or otherwise acquired, sold or otherwise disposed, gifts,
mortgages, heritage and grants, allotments and exercise of
options.
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq
Copenhagen and ADRs listed on New York Stock Exchange, except for
ADRs held in 401(k) retirement plan by US-based employees. The ID
code is the code (ISIN DK0060534915) of the Novo Nordisk share on
the Nasdaq Copenhagen or the code (NVO) on New York Stock
Exchange.
What is date and place of transaction?Date of
transaction is the actual transaction date. The place of
transaction is the actual place of transaction, i.e. Nasdaq
Copenhagen or New York Stock Exchange.
What is the volume and price of transaction and
aggregated information?The volume of transaction is the
number of shares (of DKK 0.20 nominal value) or other financial
instruments traded. In case of a single transaction the price is
the price of that single transaction. In case of multiple
transactions, when the transactions relate to the same financial
instrument, are of the same nature, are executed on the same day
and are executed on the same place, the volume must be aggregated.
The price of the aggregated transactions is the weighted average
price.
The exchange rate of the Danish Central Bank (Nationalbanken) on
the date of transaction is used for calculating the transaction
value in DKK in case of ADRs listed on New York Stock Exchange.
About Novo Nordisk A/SNovo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat diabetes and
other serious chronic diseases such as obesity and rare blood and
endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to
prevent and ultimately cure disease. Novo Nordisk employs about
47,000 people in 80 countries and markets its products in around
170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com,
Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079
3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075
2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075
2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077
6915 |
dhel@novonordisk.com |
Mark Joseph
Root |
+45 3079
4211 |
mjhr@novonordisk.com |
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024